ImmunityBio, Inc. IBRX · Stock Open ImmunityBio, Inc. in new tab
ImmunityBio, Inc. Analysis (IBRX)
Is ImmunityBio, Inc. a good investment? ImmunityBio, Inc. (IBRX) is currently trading at 7.15 USD. Market analysts have a consensus price target of 12.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: ImmunityBio, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 0.06.
Investor FAQ
Does ImmunityBio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is ImmunityBio, Inc.?
ImmunityBio, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -0.85.
Company Profile
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Community Discussion